Of our top holdings, Lifecore faces the most uncertainty in "getting there." But why do we think the path exists? Click here ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Well, welcome to the 45th Annual TD Cowen Healthcare Conference. I'm Dan Brennan, follow Tools and Diagnostics. Really pleased to be joined on stage here with Marc Casper, Chairman and President of ...

again leading to a loss of market share. Medicare has also selected NVO’s semaglutide medicines for the second round of price negotiations in 2025, which is likely to negatively impact the ...

Elliott is known for building positions in beaten-down companies and pushing for changes in leadership and strategy to raise the stock price. BP shares responded ... a 16-year high as the company ...

From its January 2010 inception through the end of October 2024, the A share class' annualized return of 6.9%(in GBP) is ahead of its OECD G7 Consumer Price ... positions in Catalent, Amazon.com ...

The portfolio can look aggressive by many measures, with average price multiples and growth rates ... from coronavirus-related spending, such as Catalent and West Pharmaceutical Services, suffered ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Novo Nordisk A/S (NVO)'s share was trading at $81.79 as of Feb ... A key milestone for the company was the acquisition of Catalent sites, which expands its global fill-and-finish capabilities ...